
Partner
Hogan Lovells US LLC
UCLA SOL; Los Angeles CA
Columns
Title | Category | Published |
---|---|---|
Bribery busts take a backseat: Trump's FCPA shift puts cartels in the spotlight | CorporateFeb. 26, 2025 | |
Keeping a watchful eye on the Corporate Compliance Program rule breakers | CorporateMar. 1, 2024 | |
Bribery and corruption enforcement and ESG are increasingly intertwined | International Law, ESG, BankingFeb. 24, 2023 | |
Assets linked to Russian oligarchs could put California in the crosshairs | May 27, 2022 | |
Balancing growth and compliance: the compliance leaders’ dilemma | Apr. 10, 2020 |
Verdicts & Settlements
Case Name | Topic | Role | Published |
---|---|---|---|
United States of America v. Med-Pharmex Inc., Gerald P. Macedo, Vinay M. Rangnekar, Ph.D. | Consumer Law | Defendant | Jan. 14, 2022 |
Gregory Allen Franklin v. Drug Enforcement Administration, et al. | Civil Rights | Defendant | Apr. 23, 2016 |
Nawal Gad v. United States of America, and Does 1 through 50 | Personal Injury | Defendant | Aug. 15, 2015 |
Title | Category | Published |
---|---|---|
Bribery busts take a backseat: Trump's FCPA shift puts cartels in the spotlight | CorporateFeb. 26, 2025 | |
Keeping a watchful eye on the Corporate Compliance Program rule breakers | CorporateMar. 1, 2024 | |
Bribery and corruption enforcement and ESG are increasingly intertwined | International Law, ESG, BankingFeb. 24, 2023 | |
Assets linked to Russian oligarchs could put California in the crosshairs | May 27, 2022 | |
Balancing growth and compliance: the compliance leaders’ dilemma | Apr. 10, 2020 |
Case Name | Topic | Role | Published |
---|---|---|---|
United States of America v. Med-Pharmex Inc., Gerald P. Macedo, Vinay M. Rangnekar, Ph.D. | Consumer Law | Defendant | Jan. 14, 2022 |
Gregory Allen Franklin v. Drug Enforcement Administration, et al. | Civil Rights | Defendant | Apr. 23, 2016 |
Nawal Gad v. United States of America, and Does 1 through 50 | Personal Injury | Defendant | Aug. 15, 2015 |